News

Long-Term Cardiovascular Adverse Events Among Survivors of Endometrial Cancer

05/08/2020

Survivors of uterine cancer are at higher risk of experiencing cardiovascular problems years after treatment.

Survivors of uterine cancer are...

05/08/2020

Oncology

News

Lenvatinib–Pembrolizumab Shows Potential in Advanced Endometrial Cancer

03/24/2020

Lenvatinib plus pembrolizumab has shown promise in patients with advanced endometrial cancer, regardless of tumor MSI status.

Lenvatinib plus pembrolizumab...

03/24/2020

Oncology

News

FDA Approves Pembrolizumab–Lenvatinib Combo for Endometrial Carcinoma

09/17/2019

The FDA granted accelerated approval to the combination of pembrolizumab and lenvatinib for the treatment of advanced endometrial carcinoma that is not MSI-H or dMMR, and disease that progresses following prior systemic therapy.

The FDA granted accelerated...

09/17/2019

Oncology

News

Adjuvant Chemoradiotherapy Improves OS vs Radiotherapy in High-Risk Endometrial Cancer

08/29/2019

Combining adjuvant chemo with radiotherapy significantly improved OS and RFS versus radiotherapy alone in women with high-risk endometrial cancer.

Combining adjuvant chemo with...

08/29/2019

Oncology

News

Adjuvant Pelvic Radiotherapy Appropriate Treatment for Early-Stage Endometrial Cancers

05/06/2019

A recent study did not demonstrate the superiority of vaginal cuff brachytherapy plus chemotherapy over pelvic radiation therapy in patients with early-stage endometrial cancer.

A recent study did not...

05/06/2019

Oncology

News

Lenvatinib–Pembrolizumab Combo Promising for Treatment of Endometrial Cancer

04/10/2019

Results from a phase 2 trial suggest that lenvatinib plus pembrolizumab is a novel combination therapy option for patients with advanced recurrent endometrial cancer.

Results from a phase 2 trial...

04/10/2019

Oncology

News

Adjuvant Taxane Plus Platinum Can Replace Doxorubicin Plus Cisplatin in Endometrial Cancer

04/08/2019

Regimens combining taxane and platinum are feasible alternatives to doxorubicin plus cisplatin in adjuvant chemotherapy for patients with endometrial cancer.

Regimens combining taxane and...

04/08/2019

Oncology

News

Minimally Invasive Endometrial Surgery Leads to Fewer Severe Complications

03/01/2019

Implementation of minimally invasive robotic surgery for early stage endometrial cancer has been associated with a reduced risk for severe complications.

Implementation of minimally...

03/01/2019

Oncology

News

Adjuvant Chemoradiation May Be Considered for High-Risk Endometrial Cancer

03/02/2018

Adjuvant chemotherapy given during and after pelvic radiation for high-risk endometrial cancer improves failure-free, but not overall, survival at five years and may be discussed as an alternative to radiation alone.

Adjuvant chemotherapy given...

03/02/2018

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology